Specialty Pharmacy

Entrectinib showed a durable response and reduced tumors in patients with ROS1-positive non-small cell lung cancer.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.

An interactive text messaging intervention improves pre-exposure prophylaxis (PrEP) adherence in a study of young people at risk for HIV.

A combination regimen of a CTLA4 targeted therapy and a PD-1 targeted therapy could be beneficial in treating ovarian cancer.

Top news of the day from across the health care landscape.

A federal bill that would lift ‘gag clauses’ prohibiting pharmacists from sharing prescription drug prices with customers was unanimously passed by the House of Representatives Tuesday.

Several hurdles remain for biosimilars to flourish in the US market.

How the re-emergence of social media tribes has shifted patient expectations of specialty pharmacy communication

In this video, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx Specialty Pharmacy explains the significance of patient centered care at PantheRx and in specialty pharmacy as a whole.

Majority of older patients with cancer and those who survived the disease found to have high levels of social and psychological wellbeing.

A pair of new studies is shedding light on a rare, but scientifically important, group of people with HIV who are able to maintain viral control even after stopping antiretroviral therapy.

Officials with Gilead Sciences, Inc. plan to launch authorized generic versions of Epclusa and Harvoni.

The US Preventive Services Task Force recommends against routine screening for prostate cancer in men 70 years of age and older.

In this clip, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx Specialty Pharmacy, explains how orphan drugs are making an impact on patients in the era of precision medicine.

Financial modeling tool shows research and development lacking of new vaccine candidates for HIV, tuberculosis, and malaria.

By mapping out the epigenomic landscape of rheumatoid arthritis, scientists hope to gain insight on disease origins as well as new cell signaling pathways.

The CLL/SLL indication is a standard approval and the follicular lymphoma indication is an accelerated approval contingent on the results of a confirmatory trial

A mobile app technology used to identify and track symptom relief helped measure real-time cannabis use.

In this video, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx, describes the methods of patient support used by PantheRx throughout treatment to provide optimal care.

Diets high in foods such as vegetables, fruit, and healthy fats found to lower the risk of death from all causes, cardiovascular disease, and cancer.

The American Hospital Association (AHA) and individual hospitals have initiated new principles for ensuring good stewardship of the 340B drug program.

A new report has found mortality rates for 5 of the 12 leading causes of death in the United States have increased since 2000.

A national survey demonstrated gaps in medical providers’ knowledge about changes to HIV health care delivery due to the Affordable Care Act.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety profile currently described in the drug label.

Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.

The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.